Purpose of Review
Biologics for the treatment of inflammatory bowel disease (IBD) have been transformative to the therapeutic goals in the pediatric population. We review the biologics used to treat IBD, highlighting the importance of patient selection, dosing considerations, and therapeutic drug monitoring in children.
Infliximab is well-established as a safe and efficacious therapy for Crohn’s disease and ulcerative colitis. Both dose escalation strategies and therapeutic drug monitoring increase the likelihood of response to anti-TNFα therapies. Early real-world experience of vedolizumab and ustekinumab in pediatric IBD shows promising results, including clinical response rates comparable to what is seen in adults, but there are limited data using them as first-line therapies.
Biologic therapies have improved outcomes in pediatric IBD, including achieving mucosal healing as well as improved growth and pubertal development. Therapeutic drug monitoring improves likelihood of response to anti-TNFα therapies, but further studies for vedolizumab and ustekinumab are necessary.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Acute severe colitis
- CD :
Inflammatory bowel disease
Inflammatory bowel disease–unclassified
Yumor necrosis factor alpha
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Iacomino G, Rotondi Aufiero V, Iannaccone N, Melina R, Giardullo N, De Chiara G, et al. IBD: role of intestinal compartments in the mucosal immune response. Immunobiology. 2019:151849. https://doi.org/10.1016/j.imbio.2019.09.008.
Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–35. https://doi.org/10.1056/NEJM199710093371502.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9. https://doi.org/10.1016/S0140-6736(02)08512-4.
Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132(3):863–73; quiz 1165-6. https://doi.org/10.1053/j.gastro.2006.12.003.
Walters TD, Kim MO, Denson LA, Griffiths AM, Dubinsky M, Markowitz J, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn's disease. Gastroenterology. 2014;146(2):383–91. https://doi.org/10.1053/j.gastro.2013.10.027.
•• Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of Paediatric Ulcerative Colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):257–91. https://doi.org/10.1097/MPG.0000000000002035. This is manuscript provides evidence based management guidelines for pediatric ulcerative colitis.
Bolia R, Rajanayagam J, Hardikar W, Alex G. Impact of changing treatment strategies on outcomes in pediatric ulcerative colitis. Inflamm Bowel Dis. 2019;25(11):1838–44. https://doi.org/10.1093/ibd/izz072.
Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Stephens M, Evans J, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol. 2010;105(6):1430–6. https://doi.org/10.1038/ajg.2009.759.
Turner D, Mack D, Leleiko N, Walters TD, Uusoue K, Leach ST, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138(7):2282–91. https://doi.org/10.1053/j.gastro.2010.02.047.
•• Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, Carpi JM, Bronsky J, et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis; an evidence-based consensus guideline from ECCO and ESPGHAN. J Pediatr Gastroenterol Nutr. 2018. https://doi.org/10.1097/MPG.0000000000002036. These are clinical guidelines aimed to standardize the treatment of pediatric acute severe colitis based on current evidence.
Falaiye TO, Mitchell KR, Lu Z, Saville BR, Horst SN, Moulton DE, et al. Outcomes following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant IBD. J Pediatr Gastroenterol Nutr. 2014;58(2):213–9. https://doi.org/10.1097/MPG.0b013e3182a98df2.
Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48(5):297–308. https://doi.org/10.5414/cpp48297.
Scaldaferri F, D'Ambrosio D, Holleran G, Poscia A, Petito V, Lopetuso L, et al. Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with infliximab. PLoS One. 2017;12(10):e0186575. https://doi.org/10.1371/journal.pone.0186575.
• Kugathasan S, Denson LA, Walters TD, Kim MO, Marigorta UM, Schirmer M, et al. Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. Lancet. 2017;389(10080):1710–8. https://doi.org/10.1016/S0140-6736(17)30317-3. This is largest pediatric cohort following newly diagnosed inflammatory Crohn disease longitudinally to determine biomarkers predictive of risk for developing complicated disease behavior.
Church PC, Ho S, Sharma A, Tomalty D, Frost K, Muise A, et al. Intensified infliximab induction is associated with improved response and decreased colectomy in steroid-refractory paediatric ulcerative colitis. J Crohns Colitis. 2019;13(8):982–9. https://doi.org/10.1093/ecco-jcc/jjz019.
Gibson DJ, Heetun ZS, Redmond CE, Nanda KS, Keegan D, Byrne K, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(2):330–5 e1. https://doi.org/10.1016/j.cgh.2014.07.041.
Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4(10):1248–54. https://doi.org/10.1016/j.cgh.2006.06.025.
Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59(1):49–54. https://doi.org/10.1136/gut.2009.183095.
Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 2015;64(10):1539–45. https://doi.org/10.1136/gutjnl-2014-307883.
Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT. Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn's disease. Inflamm Bowel Dis. 2018;24(10):2266–71. https://doi.org/10.1093/ibd/izy132.
Hofmekler T, Bertha M, McCracken C, Martineau B, McKinnon E, Schoen BT, et al. Infliximab optimization based on therapeutic drug monitoring in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2017;64(4):580–5. https://doi.org/10.1097/MPG.0000000000001302.
Rosen MJ, Minar P, Vinks AA. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2015;41(11):1094–103. https://doi.org/10.1111/apt.13175.
Ungar B, Glidai Y, Yavzori M, Picard O, Fudim E, Lahad A, et al. Association between infliximab drug and antibody levels and therapy outcome in pediatric inflammatory bowel diseases. J Pediatr Gastroenterol Nutr. 2018;67(4):507–12. https://doi.org/10.1097/MPG.0000000000002051.
Courbette O, Aupiais C, Viala J, Hugot JP, Roblin X, Candon S, et al. Trough levels of infliximab at W6 are predictive of remission at W14 in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2019;70:310–7. https://doi.org/10.1097/MPG.0000000000002536.
Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108(6):962–71. https://doi.org/10.1038/ajg.2013.12.
Ungar B, Levy I, Yavne Y, Yavzori M, Picard O, Fudim E, et al. Optimizing anti-TNF-alpha therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14(4):550–7 e2. https://doi.org/10.1016/j.cgh.2015.10.025.
Yarur AJ, Kanagala V, Stein DJ, Czul F, Quintero MA, Agrawal D, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. Aliment Pharmacol Ther. 2017;45(7):933–40. https://doi.org/10.1111/apt.13970.
Aardoom MA, Joosse ME, de Vries ACH, Levine A, de Ridder L. Malignancy and mortality in pediatric-onset inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2018;24(4):732–41. https://doi.org/10.1093/ibd/izx104.
Olen O, Askling J, Sachs MC, Frumento P, Neovius M, Smedby KE, et al. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014. BMJ. 2017;358:j3951. https://doi.org/10.1136/bmj.j3951.
•• Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher J, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152(8):1901–14.e3. https://doi.org/10.1053/j.gastro.2017.02.004. This is the largest longitudinal pediatric cohort with IBD aimed to determine risks of malignancy and lymphoproliferative disorders associated with immunosuppressive treatments.
Friesen CA, Calabro C, Christenson K, Carpenter E, Welchert E, Daniel JF, et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2004;39(3):265–9. https://doi.org/10.1097/00005176-200409000-00008.
Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63(4):567–77. https://doi.org/10.1136/gutjnl-2012-302853.
Andersen NN, Jess T. Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol. 2014;20(43):16014–9. https://doi.org/10.3748/wjg.v20.i43.16014.
Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12(9):1443–51; quiz e88–9. https://doi.org/10.1016/j.cgh.2014.01.021.
Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA Jr, Colletti RB, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology. 2012;143(2):365–74 e2. https://doi.org/10.1053/j.gastro.2012.04.046.
Ruemmele FM, Rosh J, Faubion WA, Dubinsky MC, Turner D, Lazar A, et al. Efficacy of Adalimumab for treatment of perianal fistula in children with moderately to severely active Crohn's disease: results from IMAgINE 1 and IMAgINE 2. J Crohns Colitis. 2018;12(10):1249–54. https://doi.org/10.1093/ecco-jcc/jjy087.
Walters TD, Faubion WA, Griffiths AM, Baldassano RN, Escher J, Ruemmele FM, et al. Growth improvement with adalimumab treatment in children with moderately to severely active Crohn's disease. Inflamm Bowel Dis. 2017;23(6):967–75. https://doi.org/10.1097/MIB.0000000000001075.
Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, et al. Long-term efficacy and safety of adalimumab in pediatric patients with Crohn's disease. Inflamm Bowel Dis. 2017;23(3):453–60. https://doi.org/10.1097/MIB.0000000000001021.
Kestens C, van Oijen MG, Mulder CL, van Bodegraven AA, Dijkstra G, de Jong D, et al. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-alpha agents. Clin Gastroenterol Hepatol. 2013;11(7):826–31. https://doi.org/10.1016/j.cgh.2013.01.012.
Doecke JD, Hartnell F, Bampton P, Bell S, Mahy G, Grover Z, et al. Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study. Aliment Pharmacol Ther. 2017;45(4):542–52. https://doi.org/10.1111/apt.13880.
Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-Biroulet L. Treatment persistence for infliximab versus adalimumab in Crohn's disease: a 14-year single-center experience. Inflamm Bowel Dis. 2017;23(6):976–85. https://doi.org/10.1097/MIB.0000000000001072.
Ananthakrishnan AN, Cagan A, Cai T, Gainer VS, Shaw SY, Savova G, et al. Comparative effectiveness of infliximab and adalimumab in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2016;22(4):880–5. https://doi.org/10.1097/MIB.0000000000000754.
Dubinsky MC, Rosh J, Faubion WA Jr, Kierkus J, Ruemmele F, Hyams JS, et al. Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn's disease. Inflamm Bowel Dis. 2016;22(4):886–93. https://doi.org/10.1097/MIB.0000000000000715.
Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J Crohns Colitis. 2018;12(6):635–43. https://doi.org/10.1093/ecco-jcc/jjy004.
Cozijnsen M, Duif V, Kokke F, Kindermann A, van Rheenen P, de Meij T, et al. Adalimumab therapy in children with Crohn disease previously treated with infliximab. J Pediatr Gastroenterol Nutr. 2015;60(2):205–10. https://doi.org/10.1097/MPG.0000000000000589.
Aloi M, Bramuzzo M, Arrigo S, Romano C, D'Arcangelo G, Lacorte D, et al. Efficacy and safety of adalimumab in pediatric ulcerative colitis: a real-life experience from the SIGENP-IBD registry. J Pediatr Gastroenterol Nutr. 2018;66(6):920–5. https://doi.org/10.1097/MPG.0000000000001883.
Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: an indirect treatment comparison meta-analysis. J Crohns Colitis. 2014;8(7):571–81. https://doi.org/10.1016/j.crohns.2014.01.010.
Singh S, Andersen NN, Andersson M, Loftus EV Jr, Jess T. Comparison of infliximab and adalimumab in biologic-naive patients with ulcerative colitis: a Nationwide Danish cohort study. Clin Gastroenterol Hepatol. 2017;15(8):1218–25 e7. https://doi.org/10.1016/j.cgh.2016.11.024.
Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413. https://doi.org/10.14309/ajg.0000000000000152.
Assa A, Matar M, Turner D, Broide E, Weiss B, Ledder O, et al. Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn's disease compared with reactive monitoring. Gastroenterology. 2019;157(4):985–96 e2. https://doi.org/10.1053/j.gastro.2019.06.003.
Mosli MH, MacDonald JK, Bickston SJ, Behm BW, Tsoulis DJ, Cheng J, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21(5):1151–9. https://doi.org/10.1097/MIB.0000000000000396.
Conrad MA, Stein RE, Maxwell EC, Albenberg L, Baldassano RN, Dawany N, et al. Vedolizumab therapy in severe pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(10):2425–31. https://doi.org/10.1097/MIB.0000000000000918.
Singh N, Rabizadeh S, Jossen J, Pittman N, Check M, Hashemi G, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(9):2121–6. https://doi.org/10.1097/MIB.0000000000000865.
Lowenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, et al. Vedolizumab induces endoscopic and histologic remission in patients with Crohn's disease. Gastroenterology. 2019;157(4):997–1006 e6. https://doi.org/10.1053/j.gastro.2019.05.067.
Jossen J, Kiernan B, Pittman N, Dubinsky MC. Anti-TNF exposure impacts vedolizumab mucosal healing rates in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2019;70:304–9. https://doi.org/10.1097/MPG.0000000000002556.
Sands BE, Peyrin-Biroulet L, Loftus EV, Danese S, Colombel J-F, Törüner M, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–26. https://doi.org/10.1056/NEJMoa1905725.
Yarur AJ, Bruss A, Naik S, Beniwal-Patel P, Fox C, Jain A, et al. Vedolizumab concentrations are associated with long-term endoscopic remission in patients with inflammatory bowel diseases. Dig Dis Sci. 2019;64(6):1651–9. https://doi.org/10.1007/s10620-019-05570-1.
Ungaro RC, Yarur A, Jossen J, Phan BL, Chefitz E, Sehgal P, et al. Higher trough vedolizumab concentrations during maintenance therapy are associated with corticosteroid-free remission in inflammatory bowel disease. J Crohns Colitis. 2019;13(8):963–9. https://doi.org/10.1093/ecco-jcc/jjz041.
Pouillon L, Rousseau H, Busby-Venner H, De Carvalho BM, Choukour M, Gauchotte G, et al. Vedolizumab trough levels and histological healing during maintenance therapy in ulcerative colitis. J Crohns Colitis. 2019;13(8):970–5. https://doi.org/10.1093/ecco-jcc/jjz029.
Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015;42(2):188–202. https://doi.org/10.1111/apt.13243.
Card T, Xu J, Liang H, Bhayat F. What is the risk of progressive multifocal leukoencephalopathy in patients with ulcerative colitis or Crohn's disease treated with vedolizumab? Inflamm Bowel Dis. 2018;24(5):953–9. https://doi.org/10.1093/ibd/izx097.
Zimmerman LA, Zalieckas JM, Shamberger RC, Bousvaros A. Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab. J Pediatr Surg. 2018;53(7):1330–3. https://doi.org/10.1016/j.jpedsurg.2017.12.001.
Park KT, Sceats L, Dehghan M, Trickey AW, Wren A, Wong JJ, et al. Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48(3):340–6. https://doi.org/10.1111/apt.14842.
Lightner AL, Tse CS, Potter DD Jr, Moir C. Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease. J Pediatr Surg. 2018;53(9):1706–9. https://doi.org/10.1016/j.jpedsurg.2017.09.019.
Kotze PG, Ma C, McKenna N, Almutairdi A, Kaplan GG, Raffals LE, et al. Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. Ther Adv Gastroenterol. 2018;11:1756284818783614. https://doi.org/10.1177/1756284818783614.
Yung DE, Horesh N, Lightner AL, Ben-Horin S, Eliakim R, Koulaouzidis A, et al. Systematic review and meta-analysis: vedolizumab and postoperative complications in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(11):2327–38. https://doi.org/10.1093/ibd/izy156.
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008;135(4):1130–41. https://doi.org/10.1053/j.gastro.2008.07.014.
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375(20):1946–60. https://doi.org/10.1056/NEJMoa1602773.
Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–14. https://doi.org/10.1056/NEJMoa1900750.
Landells I, Marano C, Hsu MC, Li S, Zhu Y, Eichenfield LF, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603. https://doi.org/10.1016/j.jaad.2015.07.002.
Dayan JR, Dolinger M, Benkov K, Dunkin D, Jossen J, Lai J, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. J Pediatr Gastroenterol Nutr. 2019;69(1):61–7. https://doi.org/10.1097/MPG.0000000000002362.
Chavannes M, Martinez-Vinson C, Hart L, Kaniki N, Chao CY, Lawrence S, et al. Management of paediatric patients with medically refractory Crohn's disease using ustekinumab: a multi-centred cohort study. J Crohns Colitis. 2019;13(5):578–84. https://doi.org/10.1093/ecco-jcc/jjy206.
Adedokun OJ, Xu Z, Marano C, O'Brien C, Szapary P, Zhang H, et al. Ustekinumab pharmacokinetics and exposure response in a phase 3 randomized trial of patients with ulcerative colitis: ustekinumab PK and exposure-response in UC. Clin Gastroenterol Hepatol. 2019. https://doi.org/10.1016/j.cgh.2019.11.059.
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Pediatric Gastroenterology
About this article
Cite this article
Conrad, M.A., Kelsen, J.R. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. Curr Gastroenterol Rep 22, 36 (2020). https://doi.org/10.1007/s11894-020-00773-3
- Pediatric inflammatory bowel disease
- Biologic therapy
- Crohn’s disease
- Ulcerative colitis
- Therapeutic drug monitoring